144 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Bought by Endeavor Private Wealth Inc.

Endeavor Private Wealth Inc. acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 144 shares of the pharmaceutical company’s stock, valued at approximately $58,000.

A number of other hedge funds have also recently made changes to their positions in VRTX. Northwest Investment Counselors LLC purchased a new position in Vertex Pharmaceuticals in the 3rd quarter worth approximately $25,000. Dunhill Financial LLC raised its position in shares of Vertex Pharmaceuticals by 70.6% during the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 24 shares during the last quarter. Highline Wealth Partners LLC bought a new position in shares of Vertex Pharmaceuticals during the third quarter worth $27,000. Legacy Investment Solutions LLC purchased a new position in Vertex Pharmaceuticals during the third quarter valued at $33,000. Finally, Truvestments Capital LLC bought a new stake in Vertex Pharmaceuticals in the 3rd quarter valued at $35,000. Institutional investors own 90.96% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Scotiabank increased their price objective on shares of Vertex Pharmaceuticals from $426.00 to $430.00 and gave the company a “sector perform” rating in a report on Monday, December 23rd. Citigroup started coverage on Vertex Pharmaceuticals in a research note on Thursday, November 14th. They set a “buy” rating and a $575.00 price target for the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Friday, December 20th. Cantor Fitzgerald reiterated an “overweight” rating and set a $480.00 target price on shares of Vertex Pharmaceuticals in a research report on Tuesday, November 5th. Finally, UBS Group lifted their target price on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $490.38.

Vertex Pharmaceuticals Stock Up 0.0 %

Shares of VRTX stock opened at $428.00 on Thursday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The firm has a market capitalization of $110.22 billion, a PE ratio of -215.08, a P/E/G ratio of 2.20 and a beta of 0.40. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. The stock’s 50-day simple moving average is $436.77 and its 200-day simple moving average is $465.13.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating the consensus estimate of $3.61 by $0.77. The company had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The firm’s revenue was up 11.6% on a year-over-year basis. During the same period in the prior year, the company earned $3.67 earnings per share. Equities analysts expect that Vertex Pharmaceuticals Incorporated will post -1.9 earnings per share for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.